Avoid common mistakes on your manuscript.
Correction to: Diabetes Ther (2024) 15:145–154https://doi.org/10.1007/s13300-023-01489-z
In this article, the text ‘IDegLira can be prescribed in T2D alone or in combination with other oral anti-hyperglycemic agents or in combination with short-acting insulin when glycemic control is poor’ should have read ‘IDegLira can be prescribed in T2D as an adjunct to diet and exercise in addition to other oral medicinal products for the treatment of diabetes. IDegLira is indicated in the transfer from any prior insulin regimen that includes a basal insulin component (including multi-injection regimens)’.
The original article has been corrected.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Romano, I., Serra, R. Correction to: Use of IDegLira to Intensify, Simplify, and Increase Appropriateness of Type 2 Diabetes Therapy: A Real-Life Experience. Diabetes Ther 15, 1483 (2024). https://doi.org/10.1007/s13300-024-01576-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13300-024-01576-9